144 related articles for article (PubMed ID: 36273254)
1. Occurrence of voriconazole-induced cutaneous squamous cell carcinoma in Japan: data mining from different national pharmacovigilance databases.
Tanaka H; Okuma M; Ishii T
Pharmazie; 2022 Oct; 77(10):307-310. PubMed ID: 36273254
[TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA's adverse events reporting system.
Jean-Pierre P; Nouri K
Arch Dermatol Res; 2024 May; 316(6):250. PubMed ID: 38795220
[TBL] [Abstract][Full Text] [Related]
3. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
4. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
5. The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis.
Kosmidis C; Mackenzie A; Harris C; Hashad R; Lynch F; Denning DW
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2233-2237. PubMed ID: 32820348
[TBL] [Abstract][Full Text] [Related]
6. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS.
Ando G; Taguchi K; Enoki Y; Yokoyama Y; Kizu J; Matsumoto K
Biol Pharm Bull; 2019; 42(11):1799-1804. PubMed ID: 31685764
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
[TBL] [Abstract][Full Text] [Related]
9. Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.
Hosohata K; Inada A; Oyama S; Niinomi I; Wakabayashi T; Iwanaga K
Clin Drug Investig; 2019 Apr; 39(4):363-368. PubMed ID: 30689189
[TBL] [Abstract][Full Text] [Related]
10. Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases.
Ohyama K; Tanaka H; Shindo J; Shibayama M; Iwata M; Hori Y
Int J Clin Pharmacol Ther; 2022 Jan; 60(1):24-31. PubMed ID: 34622771
[TBL] [Abstract][Full Text] [Related]
11. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
12. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
13. Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
Tanaka J; Koseki T; Kondo M; Ito Y; Yamada S
Anticancer Res; 2022 Sep; 42(9):4439-4451. PubMed ID: 36039456
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance Assessment of Drug-Induced Acute Pancreatitis Using a Spontaneous Reporting Database.
Niinomi I; Hosohata K; Oyama S; Inada A; Wakabayashi T; Iwanaga K
Int J Toxicol; 2019; 38(6):487-492. PubMed ID: 31470743
[TBL] [Abstract][Full Text] [Related]
15. Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database.
Sato K; Mano T; Iwata A; Toda T
J Alzheimers Dis; 2021; 82(3):1333-1344. PubMed ID: 34151816
[TBL] [Abstract][Full Text] [Related]
16. Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database.
Inada A; Oyama S; Niinomi I; Wakabayashi T; Iwanaga K; Hosohata K
J Clin Pharm Ther; 2019 Oct; 44(5):775-779. PubMed ID: 31231846
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases.
Shiraishi C; Hirai T; Ogura T; Iwamoto T
Anticancer Res; 2023 Feb; 43(2):883-891. PubMed ID: 36697083
[TBL] [Abstract][Full Text] [Related]
18. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
[TBL] [Abstract][Full Text] [Related]
19. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
20. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
